BioSerenity Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
270
- Latest Deal Type
-
2ndary - Private
- Investors
-
11
BioSerenity General Information
Description
Developer of electrophysiology diagnostic systems designed to diagnose neurological, sleep, and cardiac disorders. The company develops connected medical devices featuring EEG systems and wearable sensors, along with an AI-powered software platform for EEG analysis, seizure detection, and clinical decision support, enabling healthcare providers to perform accurate and remote diagnostics.
Contact Information
Website
www.bioserenity.aiCorporate Office
- 6/8 Rue Jean Antoine de Baïf
- 75013 Paris
- France
Corporate Office
- 6/8 Rue Jean Antoine de Baïf
- 75013 Paris
- France
BioSerenity Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Secondary Transaction - Private | 01-May-2026 | Completed | Generating Revenue | |||
| 12. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 11. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 10. Later Stage VC | 13-Nov-2023 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 8. Later Stage VC | 05-Nov-2019 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 18-Jun-2019 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A) | 20-Sep-2017 | Completed | Startup | |||
| 5. Early Stage VC | 29-Jun-2016 | $3.35M | Completed | Startup | ||
| 4. Accelerator/Incubator | $3.35M | Completed | Startup |
BioSerenity Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Shares | ||||||||
| B Shares | ||||||||
| B Shares | ||||||||
| B Shares | ||||||||
| B Shares | 13,446 | $1.122006 | $166.89 | $166.89 | 1x | $166.89 | 2.37% | |
| A Shares | 66,936 | $1.122006 | $50.29 | $50.29 | 1x | $50.29 | 11.79% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BioSerenity Comparisons
Industry
Financing
Details
BioSerenity Competitors (25)
One of BioSerenity’s 25 competitors is NeuroVigil, a Venture Capital-Backed company based in Mountain View, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroVigil | Venture Capital-Backed | Mountain View, CA | ||||
| AliveCor | Venture Capital-Backed | Mountain View, CA | ||||
| Agatsa | Venture Capital-Backed | Noida, India | ||||
| CloudTag | Formerly PE-Backed | Kingstown, Saint Vincent | ||||
| Tricog Health | Venture Capital-Backed | Bengaluru, India |
BioSerenity Patents
BioSerenity Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4759234-A1 | Device for generating a pretrained foundation model, device for obtaining a representation of an input eeg segment and related methods | Pending | 10-Mar-2025 | ||
| WO-2026190121-A1 | Device for generating a pretrained foundation model, device for obtaining a representation of an input eeg segment and related methods | Pending | 10-Mar-2025 | ||
| EP-4751645-A1 | Preamplifier for biosignal recorder | Pending | 28-Nov-2024 | ||
| WO-2026114534-A1 | Preamplifier for biosignal recorder | Pending | 28-Nov-2024 | ||
| US-20220409048-A1 | Systems, methods, and apparatuses for detecting and quantifying biological fluids | Inactive | 23-Jun-2021 | A61B5/0537 |
BioSerenity Signals
BioSerenity Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Jolt Capital | Growth/Expansion | Minority | ||
| SCOR Global Life Americas | Corporation | Minority | ||
| Dassault Systemes | Corporation | Minority | ||
| Eurazeo PME | PE/Buyout | Minority | ||
| SCOR Ventures | Corporate Venture Capital | Minority |
BioSerenity Investments & Acquisitions (2)
BioSerenity’s most recent deal was a Later Stage VC with BOYDSense for . The deal was made on 05-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BOYDSense | 05-Apr-2024 | Later Stage VC | Monitoring Equipment | ||
| SleepMed | 08-Jun-2019 | Merger/Acquisition | Laboratory Services (Healthcare) |
BioSerenity FAQs
-
When was BioSerenity founded?
BioSerenity was founded in 2013.
-
Where is BioSerenity headquartered?
BioSerenity is headquartered in Paris, France.
-
What is the size of BioSerenity?
BioSerenity has 270 total employees.
-
What industry is BioSerenity in?
BioSerenity’s primary industry is Diagnostic Equipment.
-
Is BioSerenity a private or public company?
BioSerenity is a Private company.
-
What is BioSerenity’s current revenue?
The current revenue for BioSerenity is .
-
How much funding has BioSerenity raised over time?
BioSerenity has raised $118M.
-
Who are BioSerenity’s investors?
Jolt Capital, SCOR Global Life Americas, Dassault Systemes, Eurazeo PME, and SCOR Ventures are 5 of 11 investors who have invested in BioSerenity.
-
Who are BioSerenity’s competitors?
NeuroVigil, AliveCor, Agatsa, CloudTag, and Tricog Health are some of the 25 competitors of BioSerenity.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process